Ultragenyx Pharmaceutical (NASDAQ:RARE) Reaches New 12-Month Low – Time to Sell?

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) shares reached a new 52-week low on Monday . The company traded as low as $13.80 and last traded at $13.8410, with a volume of 880219 shares changing hands. The stock had previously closed at $14.30.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on RARE. Evercore cut Ultragenyx Pharmaceutical from an “outperform” rating to an “in-line” rating and set a $16.00 target price on the stock. in a research report on Thursday, September 3rd. JPMorgan Chase & Co. downgraded Ultragenyx Pharmaceutical from an “overweight” rating to a “neutral” rating and lowered their price target for the stock from $80.00 to $36.00 in a research report on Thursday, September 3rd. Wedbush cut their price objective on Ultragenyx Pharmaceutical from $30.00 to $23.00 and set a “neutral” rating for the company in a research report on Thursday, September 3rd. TD Cowen reduced their target price on Ultragenyx Pharmaceutical from $49.00 to $18.00 and set a “buy” rating for the company in a research note on Thursday, September 3rd. Finally, Robert W. Baird lowered Ultragenyx Pharmaceutical from an “outperform” rating to a “neutral” rating and decreased their target price for the company from $40.00 to $16.00 in a research report on Thursday, September 3rd. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $36.63.

Ultragenyx Pharmaceutical Trading Down 3.1%

The business has a fifty day simple moving average of $25.96 and a two-hundred day simple moving average of $24.76. The company has a market cap of $1.37 billion, a PE ratio of -2.38 and a beta of 0.31.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its earnings results on Tuesday, August 4th. The biopharmaceutical company reported ($0.90) EPS for the quarter, beating analysts’ consensus estimates of ($1.22) by $0.32. Ultragenyx Pharmaceutical had a negative net margin of 81.79% and a negative return on equity of 1,024.42%. The business had revenue of $214.00 million during the quarter, compared to analysts’ expectations of $183.08 million. During the same period in the prior year, the business earned ($1.17) earnings per share. The company’s quarterly revenue was up 28.5% compared to the same quarter last year. Equities analysts expect that Ultragenyx Pharmaceutical Inc. will post -3.98 EPS for the current year.

Hedge Funds Weigh In On Ultragenyx Pharmaceutical

A number of institutional investors have recently added to or reduced their stakes in RARE. Versant Capital Management Inc grew its holdings in shares of Ultragenyx Pharmaceutical by 662.9% in the second quarter. Versant Capital Management Inc now owns 1,152 shares of the biopharmaceutical company’s stock valued at $38,000 after purchasing an additional 1,001 shares during the period. Danske Bank A S purchased a new position in Ultragenyx Pharmaceutical during the third quarter worth about $39,000. Quantbot Technologies LP purchased a new position in Ultragenyx Pharmaceutical during the second quarter worth about $48,000. Harbor Investment Advisory LLC acquired a new position in Ultragenyx Pharmaceutical in the 2nd quarter valued at about $52,000. Finally, Parallel Advisors LLC boosted its holdings in Ultragenyx Pharmaceutical by 778.4% in the 1st quarter. Parallel Advisors LLC now owns 1,625 shares of the biopharmaceutical company’s stock valued at $34,000 after purchasing an additional 1,440 shares during the last quarter. Hedge funds and other institutional investors own 97.67% of the company’s stock.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing treatments for rare and ultra-rare diseases. The company’s work includes therapies for genetic, metabolic and skeletal disorders, with an emphasis on conditions that have limited or no effective treatment options.

Ultragenyx’s marketed products include Crysvita (burosumab), used to treat certain forms of X-linked hypophosphatemia and tumor-induced osteomalacia; Dojolvi (triheptanoin), a medical food for long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab), a treatment for homozygous familial hypercholesterolemia.